Drug resistance mechanism of pemetrexed in non-small cell lung cancer

doi:10.19803/j.1672-8629.20230430

Abstract

Abstract: Objective To investigate the resistance mechanism of pemetrexed in non-small cell lung cancer (NSCLC). Methods The possible mechanism of pemetrexed resistance in non-small cell lung cancer was described in terms of oncogenes, DNA synthesis and repair, and biological behavior. Results Gene mutations and related molecular changes (including EGFR, ALK, ROS1, KRAS, and NRAS, TTF-1, HDAC), changes in pemetrexed target enzymes (TS, DHFR, and GARFT and RRM1, and MTHFR), high status of DNA repair systems (including BER, NER, and CHK1, MSH2, and Ku proteins), changes in tumor migration and metastatic processes (activation of EMT, cancer cell stem cells and biomarkers) could possibly be factors contributing to the reduced sensitivity of NSCLC cells to pemetrexed. Conclusion The mechanisms of pemetrexed resistance are diverse, and treatment regimens can be selected according to the specific genotypes of NSCLC patients to improve the progression-free survival and survival rate.

Key words: non-small cell lung cancer, TS inhibitor, pemetrexed, drug resistance

CLC Number:

R979.1

LIN Qiqi, LI Xinyang, MENG Fanhao. Drug resistance mechanism of pemetrexed in non-small cell lung cancer[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1201-1208.

References

[1] ZHANG CH, XIE YJ, PENG TT, et al.Efficacy and safety of osimertinib in the treatment of egfr-mutated advanced non-small cell lung cancer:a meta-analysis[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(2): 178-183.
[2] RECK M, RODRÍGUEZ-ABREU D, ROBINSON AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50[J]. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2021, 39(21): 2339-2349.
[3] LOPCI E, ROSSI S.Tumor metabolism and prognostic role of EZH2 in non-small cell lung cancer[J]. Translational Cancer Research, 2017, 6(S6): S982-S988.
[4] ZHANG JW, DUAN DM, YUAN XS, et al.Clinical observation of thalidomide combined paclitaxel and cisplatin in treatment of advanced non-small cell lung cancer[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(8): 460-463.
[5] NAGA SAKA M, GADGEEL SM.Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer[J]. Expert Rev Anticancer Ther, 2018, 18(1): 63-70.
[6] ALHALABI O, CHEN J, ZHANG Y, et al.MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers[J]. Nature Communications, 2022, 13: 1797.
[7] SHIH JY, INOUE A, CHENG R, et al.Does pemetrexed work in targetable, nonsquamous non-small-cell lung cancer? a narrative review[J]. Cancers, 2020, 12(9): 2658.
[8] KUMAGAI S, KOYAMA S, NISHIKAWA H.Antitumour immunity regulated by aberrant ERBB family signalling[J]. Nature Reviews Cancer, 2021, 21(3): 181-197.
[9] WU MF, HSIAO YM, HUANG CF, et al.Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells[J]. Journal of Thoracic Oncology, 2010, 5(8): 1143-1151.
[10] IGAWA S, YUICHI S, MIKIKO I, et al.EGFR mutation genotype impact on the efficacy of pemetrexed in patients with nonsquamous nonsmall cell lung cancer[J]. Asian Pacific Journal of Cancer Prevention, 2016, 17(7): 3249-3253.
[11] YU Z, LI XM, LIU SH, et al.Downregulation of both EGFR and ErbB3 improves the cellular response to pemetrexed in an established pemetrexed-resistant lung adenocarcinoma A549 cell line[J]. Oncology Reports, 2014, 31(4): 1818-1824.
[12] LU S, WU L, JIAN H, et al.Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial[J]. The Lancet Oncology, 2022, 23(9): 1167-1179.
[13] GOLDING B, LUU A, JONES R, et al.The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)[J]. Molecular Cancer, 2018, 17(1): 52.
[14] REMON J, PIGNATARO D, NOVELLO S, et al.Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer[J]. Cancer Treatment Reviews, 2021, 95: 102178.
[15] LEE HY, AHN HK, JEONG JY, et al.Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer[J]. Lung Cancer, 2013, 79(1): 40-45.
[16] PARK S, PARK TS, CHOI CM, et al.Survival benefit of pemetrexed in lung adenocarcinoma patients with anaplastic lymphoma kinase gene rearrangements[J]. Clinical Lung Cancer, 2015, 16(5): e83-e89.
[17] LEE JO, KIM TM, LEE SH, et al.Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer[J]. Journal of Thoracic Oncology, 2011, 6(9): 1474-1480.
[18] KWON JH, KIM KJ, SUNG JH, et al.Afatinib overcomes pemetrexed-acquired resistance in non-small cell lung cancer cells harboring an EML4-ALK rearrangement[J]. Cells, 2019, 8(12): 1538.
[19] CHEN YF, HSIEH MS, WU SG, et al.Efficacy of pemetrexed-based chemotherapy in patients with ros1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in east asian populations[J]. Journal of Thoracic Oncology, 2016, 11(7): 1140-1152.
[20] DEARDEN S, STEVENS J, WU YL, et al.Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)[J]. Annals of Oncology, 2013, 24(9): 2371-2376.
[21] LIANG Y, WAKELEE HA, NEAL JW.Relationship of driver oncogenes to long-term pemetrexed response in non-small-cell lung cancer[J]. Clinical Lung Cancer, 2015, 16(5): 366-373.
[22] CUI J, XU F, BAI W, et al.HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism[J]. Journal of Translational Medicine, 2023, 21(1): 125.
[23] WU SG, YANG CH, YU CJ, et al.Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations[J]. Lung Cancer, 2011, 72(3): 333-339.
[24] WU MF, HSIAO YM, HUANG CF, et al.Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells[J]. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 2010, 5(8): 1143-1151.
[25] SUN J, AHN JS, PARK K, et al.Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy[J]. Journal of Clinical Oncology, 2011, 29(15 suppl): 7579.
[26] REKHTMAN N, ANG DC, SIMA CS, et al.Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens[J]. Modern Pathology, 2011, 24(10): 1348-1359.
[27] GRØNBERG BH, LUND-IVERSEN M, STRØM EH, et al. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy[J]. Journal of Thoracic Oncology, 2013, 8(10): 1255-1264.
[28] SUN JM, HAN J, AHN JS, et al.Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy[J]. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 2011, 6(8): 1392-1399.
[29] LIU Y, HUBER RM, KIEFL R, et al.Hedgehog pathway activation might mediate pemetrexed resistance in NSCLC cells[J]. Anticancer Research, 2020, 40(3): 1451-1458.
[30] LIANG J, LU T, CHEN Z, et al.Mechanisms of resistance to pemetrexed in non-small cell lung cancer[J]. Translational Lung Cancer Research, 2019, 8(6): 1107-1118.
[31] HANAUSKE AR, EISMANN U, OBERSCHMIDT O, et al.In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression[J]. Investigational New Drugs, 2007, 25(5): 417-423.
[32] HOU J, LAMBERS M, DEN HAMER B, et al.Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy[J]. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2012, 7(1): 105-114.
[33] CHEN X, YANG Y, KATZ S.Early detection of thymidylate synthase resistance in non-small cell lung cancer with FLT-PET imaging[J]. Oncotarget, 2017, 8(47): 82705-82713.
[34] BEPLER G, SOMMERS KE, CANTOR A, et al.Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer[J]. Journal of Thoracic Oncology, 2008, 3(10): 1112-1118.
[35] CHRISTOPH DC, ASUNCION BR, HASSAN B, et al.Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed[J]. Journal of Thoracic Oncology, 2013, 8(1): 19-30.
[36] ZHANG D, OCHI N, TAKIGAWA N, et al.Establishment of pemetrexed-resistant non-small cell lung cancer cell lines[J]. Cancer Letters, 2011, 309(2): 228-235.
[37] SHIMIZU T, NAKAGAWA Y, TAKAHASHI N, et al.Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer[J]. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, 18(1): 107-112.
[38] OZASA H, OGURI T, UEMURA T, et al.Significance of thymidylate synthase for resistance to pemetrexed in lung cancer[J]. Cancer Science, 2010, 101(1): 161-166.
[39] ARÉVALO E, CASTAÑÓN E, LÓPEZ I, et al. Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed[J]. Journal of Translational Medicine, 2014, 12(1): 98.
[40] KRAWCZYK P, KUCHARCZYK T, KOWALSKI DM, et al.Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients[J]. Journal of Cancer Research and Clinical Oncology, 2014, 140(12): 2047-2057.
[41] WANG X, WANG Y, WANG Y, et al.Association of thymidylate synthase gene 3’-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC[J]. Journal of Biomedical Science, 2013, 20(1): 5.
[42] BESSE B, OLAUSSEN KA, SORIA JC.ERCC1 and RRM1: ready for prime time?[J]. Journal of Clinical Oncology, 2013, 31(8): 1050-1060.
[43] CRIDER KS, YANG TP, BERRY RJ, et al.Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate’s role[J]. Advances in Nutrition, 2012, 3(1): 21-38.
[44] SMIT EF, BURGERS SA, BIESMA B, et al.Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer[J]. Journal of Clinical Oncology, 2009, 27(12): 2038-2045.
[45] WEBLEY SD, WELSH SJ, JACKMAN AL, et al.The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition[J]. British Journal of Cancer, 2001, 85(3): 446-452.
[46] VAN TRIEST B, PINEDO HM, GIACCONE G, et al.Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors[J]. Annals of Oncology, 2000, 11(4): 385-391.
[47] WILSON PM, LABONTE MJ, LENZ HJ, et al.Inhibition of dutpase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer[J]. Molecular Cancer Therapeutics, 2012, 11(3): 616-628.
[48] WEEKS LD, FU P, GERSON SL.Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed[J]. Molecular Cancer Therapeutics, 2013, 12(10): 2248-2260.
[49] LEE SH, NOH KB, LEE JS, et al.Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin[J]. Lung Cancer, 2013, 81(1): 102-108.
[50] LIAO WY, HO CC, TSAI TH, et al.Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum[J]. Lung Cancer, 2018, 118: 90-96.
[51] GRABAUSKIENE S, BERGERON EJ, CHEN G, et al.CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells[J]. Lung Cancer, 2013, 82(3): 477-484.
[52] TUNG CL, CHIU HC, JIAN YJ, et al.Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells[J]. Experimental Cell Research, 2014, 322(2): 345-354.
[53] SHANG B, JIA Y, CHEN G, et al.Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells[J]. Respiratory Research, 2017, 18(1): 56.
[54] ZAMAGNI A, PASINI A, PIRINI F, et al.CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells[J]. International Journal of Oncology, 2020, 56(6): 1574-1584.
[55] KARAMANOU K, FRANCHI M, VYNIOS D, et al.Epithelial-to-mesenchymal transition and invadopodia markers in breast cancer: Lumican a key regulator[J]. Seminars in Cancer Biology, 2020, 62: 125-133.
[56] LIANG SQ, MARTI TM, DORN P, et al.Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer[J]. Cell Death & Disease, 2015, 6(7): e1824-e1824.
[57] CHIU LY, HSIN IL, YANG TY, et al.The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids[J]. Oncogene, 2016, 36(2): 242-253.
[58] WANG W, LIU W, CHEN Q, et al.Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy[J]. Seminars in Cancer Biology, 2022, 87: 84-97.
[59] ZHAO M, ZHANG Y, ZHANG H, et al.Hypoxia-induced cell stemness leads to drug resistance and poor prognosis in lung adenocarcinoma[J]. Lung Cancer, 2015, 87(2): 98-106.
[60] SHEN HT, CHIEN PJ, CHEN SH, et al.BMI1-mediated pemetrexed resistance in non-small cell lung cancer cells is associated with increased sp1 activation and cancer stemness[J]. Cancers, 2020, 12(8): 2069.
[61] CHANG WW, WANG BY, CHEN SH, et al.MiR-145-5p targets Sp1 in non-small cell lung cancer cells and links to Bmi1 induced pemetrexed resistance and epithelial-mesenchymal transition[J]. International Journal of Molecular Sciences, 2022, 23(23): 15352.
[62] WEN Y, GAMAZON ER, BLEIBEL WK, et al.An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers[J]. Human Molecular Genetics, 2011, 21(7): 1470-1480.
[63] CEPPI P, RAPA I, LO IACONO M, et al.Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer[J]. International Journal of Cancer, 2011, 130(8): 1777-1786.
[64] CHOU HC, CHEN JY, LIN DY, et al.Identification of up- and down-regulated proteins in pemetrexed-resistant human lung adenocarcinoma: flavin reductase and calreticulin play key roles in the development of pemetrexed-associated resistance[J]. Journal of Proteome Research, 2015, 14(11): 4907-4920.
[65] LI X, LIANG Q, ZHOU L, et al. Survivin degradation by bergenin overcomes pemetrexed resistance[J/OL]. Cellular Oncology (Dordrecht), (2023-09-09)[2023-09-01]. https://link.springer.com/journal/13402/online-first.
[66] LIAO J, QING X, DENG G, et al.Gastrodin destabilizes survivin and overcomes pemetrexed resistance[J]. Cellular Signalling, 2023, 110: 110851.
[67] SHI SB, WANG M, TIAN J, et al.MicroRNA 25 , microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations[J]. Translational Research, 2016, 170: 1-7.
[68] BUTI S, BORDI P, TISEO M, et al.Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients[J]. Lung Cancer, 2015, 88(3): 319-324.
[69] NORONHA V, PATIL VM, JOSHI A, et al.Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer[J]. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2020, 38(2): 124-136.
[70] AO L, FANG S, ZHANG K, et al.Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence[J]. Journal of Experimental & Clinical Cancer Research, 2022, 41(1): 163.
[71] SHAW AT, KIM TM, CRINÒ L, et al.Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial[J]. The Lancet. Oncology, 2017, 18(7): 874-886.
[72] SORIA JC, TAN DSW, CHIARI R, et al.First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study[J]. Lancet (London, England), 2017, 389(10072): 917-929.
[73] SHAW AT, KIM DW, NAKAGAWA K, et al.Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. The New England Journal of Medicine, 2013, 368(25): 2385-2394.
[74] CHEN Y, ZHANG C, JIN S, et al.Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC[J]. Journal of Cellular and Molecular Medicine, 2023, 27(14): 2032-2044.
[75] DAVAR D, KIRKWOOD JM.PD-1 immune checkpoint inhibitors and immune-related adverse events: understanding the upside of the downside of checkpoint blockade[J]. JAMA oncology, 2019, 5(7): 942-943.
[76] BRAHMER JR, PARDOLL DM.Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer[J]. Cancer Immunology Research, 2013, 1(2): 85-91.
[77] ARBOUR KC, RIELY GJ.Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review[J]. JAMA, 2019, 322(8): 764-774.
[78] GANDHI L, RODRÍGUEZ-ABREU D, GADGEEL S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. The New England Journal of Medicine, 2018, 378(22): 2078-2092.
[79] KIM ES.Chemotherapy resistance in lung cancer[J]. Adv Exp Med Biol, 2016, 893: 189-209.
[80] JARMULA A.Antifolate inhibitors of thymidylate synthase as anticancer drugs[J]. Mini-Reviews in Medicinal Chemistry, 2010, 10(13): 1211-1222.